Publication | Open Access

Cost-Effectiveness of Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Phase Chronic Myeloid Leukemia

Hematological MalignancyOncologyMedicineHematologyPharmacotherapyPharmacologyMyeloid Neoplasia